Giardiasis: recent progress in chemotherapy and drug development.

Giardiasis is a protozoal disease infecting 200 million people throughout the world. Giardiasis is widespread primarily in developing countries. Infections are correlated with poor hygienic conditions, poor water quality control, and overcrowding. There are very few therapeutics currently available, and drug development to treat giardiasis is hampered mainly by socioeconomic obstacles. This article presents the history of antigiardial chemotherapy and current state of therapeutic availability along with the future prospectus of development of antigiardial agents. In addition to accumulated knowledge about the previous and current antigiardial drugs, advanced technologies including computer-aided drug design and combinatorial synthetic chemistry, as well as high throughput screening techniques, accelerate understanding of the disease and further research toward a suitable antigiardial agent.
AuthorsTomoko Minenoa, Mitchell A Avery
JournalCurrent pharmaceutical design (Curr Pharm Des) Vol. 9 Issue 11 Pg. 841-55 ( 2003) ISSN: 1381-6128 [Print] Netherlands
PMID12678869 (Publication Type: Journal Article, Review)
Chemical References
  • Antiprotozoal Agents
  • DNA, Protozoan
  • Animals
  • Antiprotozoal Agents (chemistry, therapeutic use)
  • DNA, Protozoan (analysis)
  • Drug Resistance
  • Feces (microbiology)
  • Giardia lamblia (drug effects, genetics, isolation & purification)
  • Giardiasis (diagnosis, drug therapy, transmission)
  • Humans
  • Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: